Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

Part of paid clinical trials in Detroit, Michigan.

Sponsor
GlaxoSmithKline
Study ID
NCT00148902
Phase
PHASE1
Status
Completed

Conditions

  • Neoplasms, Breast

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • lapatinib — DRUG
    lapatinib
  • docetaxel — DRUG
    docetaxel

Study Details

This is a safety and tolerability study of GW572016 given with docetaxel (TAXOTERE).

Key Dates

Start date
Apr 28, 2003
Status verified
Dec 2017
Primary completion
Jan 21, 2006
Completion
Jan 21, 2006

Study Design

Enrollment
52 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: All treated subjects
    All subjects received Lapatinib in Combination with Docetaxel (Taxotere)

Primary Outcome Measure

Number of subjects with adverse events (AEs) or serious AEs (SAEs) [ Time Frame: Up to 7 weeks in each cycle ]

Locations (2)

FacilityCityStateZIPSite coordinators
GSK Investigational SiteDetroitMichigan48201-
GSK Investigational SiteNashvilleTennessee37203-

Find similar trials in Detroit, MI

By research site
GSK Investigational Site· Detroit, MIGSK Investigational Site· Nashville, TN